These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 5086359

  • 1. [Results of testing the effectiveness of live measles virus vaccine by using measles reference virus M1].
    Winkler D, Starke G, Patzwaldt HG, Plaga B.
    Pharmazie; 1972 Sep; 27(9):606-8. PubMed ID: 5086359
    [No Abstract] [Full Text] [Related]

  • 2. The lyophilization of measles virus.
    Mares I, Kittnar E, Srbová H, Casný J.
    J Hyg Epidemiol Microbiol Immunol; 1969 Sep; 13(3):279-87. PubMed ID: 5387794
    [No Abstract] [Full Text] [Related]

  • 3. [Revaccination against measles].
    Gerike E, Kirchner W, Pöhle W, Tischer A.
    Z Gesamte Hyg; 1983 Feb; 29(2):62-5. PubMed ID: 6858258
    [No Abstract] [Full Text] [Related]

  • 4. Studies on the modification of the live AIK measles vaccine. II. Development and evaluation of the live AIK-C measles vaccine.
    Makino S, Sasaki K, Nakamura N, Nakagawa M, Nakajima S.
    Kitasato Arch Exp Med; 1974 Jun; 47(1-2):13-21. PubMed ID: 4476032
    [No Abstract] [Full Text] [Related]

  • 5. Sorbitol-gelatin and glutamic acid-lactose solutions for stabilization of reference preparations of measles virus.
    de Rizzo E, Tenório EC, Mendes IF, Fang FL, Pral MM, Takata CS, Miyaki C, Gallina NM, Tuchiya HN, Akimura OK.
    Bull Pan Am Health Organ; 1989 Jun; 23(3):299-305. PubMed ID: 2571379
    [Abstract] [Full Text] [Related]

  • 6. [Problems concerning live measles vaccine and the control over its safety].
    Polna I.
    Przegl Epidemiol; 1970 Jun; 24(1):21-30. PubMed ID: 4988185
    [No Abstract] [Full Text] [Related]

  • 7. [Unsuitability of children revaccination against measles].
    Bolotovskiĭ VM, Titova NS.
    Sov Med; 1981 Jun; (9):43-8. PubMed ID: 7313794
    [No Abstract] [Full Text] [Related]

  • 8. Potency status and efficacy of measles vaccine administered in Nigeria: a case study of three EPI centres in Lagos, Nigeria.
    Omilabu SA, Oyefolu AO, Ojo OO, Audu RA.
    Afr J Med Med Sci; 1999 Jun; 28(3-4):209-12. PubMed ID: 11205835
    [Abstract] [Full Text] [Related]

  • 9. [History of purification, attenuation and testing a measles vaccine made from the strain "Leningrad-16" (L-16)].
    Smorodintsev AA, Taros LIu.
    Tr Inst Im Pastera; 1992 Jun; 67():86-95. PubMed ID: 8539772
    [No Abstract] [Full Text] [Related]

  • 10. The accelerated storage test applied in the study of thermal stability of haemagglutinating measles virus antigen.
    Serbănescu R, Munţiu V.
    Arch Roum Pathol Exp Microbiol; 1979 Jun; 38(1):81-7. PubMed ID: 546374
    [No Abstract] [Full Text] [Related]

  • 11. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines.
    Brandler S, Tangy F.
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):271-91. PubMed ID: 17869338
    [Abstract] [Full Text] [Related]

  • 12. [Age-dependence of measles immunization failures].
    Giesecke H, Brendel P, Schmidt J, Schlenk B.
    Z Gesamte Hyg; 1980 Mar; 26(10):764-67. PubMed ID: 7467503
    [No Abstract] [Full Text] [Related]

  • 13. [Control over the postvaccinal measles immunity status using the indirect hemagglutination test with lyophilized diagnostic agents].
    Sokhin AA, Sliuar' LI, Smorodinova IP, Rodomskaia FS, Makarova EN.
    Tr Inst Im Pastera; 1981 Mar; 56():121-3. PubMed ID: 7187542
    [No Abstract] [Full Text] [Related]

  • 14. Studies on the modification of the live AIK measles vaccine. I. Adaptation of the further attenuated AIK measles virus (the strain AIK-L33) to chick embryo cells.
    Sasaki K.
    Kitasato Arch Exp Med; 1974 Jun; 47(1-2):1-12. PubMed ID: 4217404
    [No Abstract] [Full Text] [Related]

  • 15. Estimation of the number of infectious measles viruses in live virus vaccines using quantitative real-time PCR.
    Schalk JA, van den Elzen C, Ovelgönne H, Baas C, Jongen PM.
    J Virol Methods; 2004 May; 117(2):179-87. PubMed ID: 15041215
    [Abstract] [Full Text] [Related]

  • 16. Optimal age for vaccinating Nigerian children against measles. II. Seroconversion to measles vaccine in different age groups.
    Ogunmekan DA, Harry TO.
    Trop Geogr Med; 1981 Dec; 33(4):379-82. PubMed ID: 7342385
    [Abstract] [Full Text] [Related]

  • 17. Wide occurrence of measles virus subgenomic RNAs in attenuated live-virus vaccines.
    Bellocq C, Mottet G, Roux L.
    Biologicals; 1990 Oct; 18(4):337-43. PubMed ID: 2285505
    [Abstract] [Full Text] [Related]

  • 18. [Results of a trial of an erythrocyte measles diagnostic agent in public health institutions].
    Polzik TP, Kashkina GB, Andrianova DP, Bol'shakova SL, Petrova MA.
    Tr Inst Im Pastera; 1981 Oct; 56():112-4. PubMed ID: 6764964
    [No Abstract] [Full Text] [Related]

  • 19. [Comparison of clinical and serological results after intramuscular and subcutaneous administration of measles vaccine].
    Domorázková E, Drevo M, Bergmannová V, Stehlíková J, Vodicková M, Slonim D.
    Cesk Pediatr; 1982 Jan; 37(1):19-22. PubMed ID: 7060187
    [No Abstract] [Full Text] [Related]

  • 20. [Results of a field study with a live measles vaccine of own production].
    Hempel HC, Starke G, Grimm J, Hlinak P, Nöbel B.
    Dtsch Gesundheitsw; 1967 Mar 23; 22(12):547-52. PubMed ID: 5593197
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.